Amphastar Pharmaceuticals Says FDA Approved Teriparatide Injection as Osteoporosis Treatment

MT Newswires Live12-15

Amphastar Pharmaceuticals (AMPH) said Monday that the US Food and Drug Administration approved the abbreviated new drug application for its teriparatide injection as a treatment for osteoporosis.

Amphastar said the teriparatide injection is intended to treat postmenopausal women with osteoporosis, to increase bone mass in men with primary or hypogonadal osteoporosis, and for patients with osteoporosis associated with sustained systemic glucocorticoid therapy.

In each of these cases, the injection is indicated for use in patients at high risk for fracture who have failed or are intolerant to other available osteoporosis therapies, the company said.

Amphastar said it plans to launch the injection, sold as a single-patient-use prefilled pen, by the end of the year.

The FDA has determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO, according to Amphastar.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment